Mai Nakano1,2, Akimitsu Miyake3, Ryuichiro Egashira1, Mariko Takeuchi1, Misaki Moriguchi1, Satoko Tonari1, Hitomi Saito1, Hiroki Nishikawa4, Kiyoshi Matsui2, Keisuke Hagihara5. 1. Department of Advanced Hybrid Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. 2. Division of Allergology and Rheumatology, Department of Diabetes Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Hyogo, Japan. 3. department of Medical Innovation, Osaka University Hospital, Suita, Japan. 4. The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan. 5. Department of Advanced Hybrid Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; k.hagihara@kanpou.med.osaka-u.ac.jp.
Abstract
BACKGROUND/AIM: To investigate factors associated with increased bone mineral density (BMD) of the neck of femur in rheumatoid arthritis or collagen diseases receiving denosumab, focusing on body composition calculated by bioelectrical impedance analysis (n=90, 78 females). PATIENTS AND METHODS: We defined Δfemur as BMD (12 months minus baseline), using dual-energy X-ray absorptiometry after denosumab therapy. Factors associated with Δfemur were retrospectively investigated. RESULTS: Low skeletal muscle index (SMI) was observed in 6 males and 32 females. There was a significant difference in phase angle (PhA) of the left leg (LL) between the Δfemur ≥0 (n=70) and Δfemur <0 (n=20) groups (p=0.040) but not in SMI (p=0.310). Multiple regression analysis indicated that PhA of LL was significantly related to Δfemur (p=0.0398). CONCLUSION: PhA appears to be a clinically significant indicator of improvement of Δfemur in patients receiving denosumab.
BACKGROUND/AIM: To investigate factors associated with increased bone mineral density (BMD) of the neck of femur in rheumatoid arthritis or collagen diseases receiving denosumab, focusing on body composition calculated by bioelectrical impedance analysis (n=90, 78 females). PATIENTS AND METHODS: We defined Δfemur as BMD (12 months minus baseline), using dual-energy X-ray absorptiometry after denosumab therapy. Factors associated with Δfemur were retrospectively investigated. RESULTS: Low skeletal muscle index (SMI) was observed in 6 males and 32 females. There was a significant difference in phase angle (PhA) of the left leg (LL) between the Δfemur ≥0 (n=70) and Δfemur <0 (n=20) groups (p=0.040) but not in SMI (p=0.310). Multiple regression analysis indicated that PhA of LL was significantly related to Δfemur (p=0.0398). CONCLUSION: PhA appears to be a clinically significant indicator of improvement of Δfemur in patients receiving denosumab.
Authors: Petra Wiedmer; Tobias Jung; José Pedro Castro; Laura C D Pomatto; Patrick Y Sun; Kelvin J A Davies; Tilman Grune Journal: Ageing Res Rev Date: 2020-10-29 Impact factor: 10.895
Authors: Julia Etich; Lennart Leßmeier; Mirko Rehberg; Helge Sill; Frank Zaucke; Christian Netzer; Oliver Semler Journal: Mol Cell Pediatr Date: 2020-08-14